

UCB at a glance

Delivering excellence

Everything we do starts with a simple question: how can we help people with severe diseases live the best life they can?

By understanding individuals' daily realities and the biology behind their conditions, we turn insight into transformative treatments across immunology, neurology and other areas where our expertise aligns with unmet needs.

By focusing our science where it matters most, we are translating differentiated innovation into strong commercial execution and sustainable performance, over the next decade and beyond.

[Immunology](#)
[Neurology](#)

- 2025 total patient number is calculated using the Moving Annual Total (MAT) patients (Estimated Actual Treated) at the end of Q3 2025 as provided with input data from an external source. The total patient number gathers people who have accessed the following solutions: BIMZELX®, BRIVIACT®, CIMZIA®, EVENITY®, FINTEPLA®, KEPPRA®, NAYZILAM®, RYSTIGGO®, VIMPAT® and ZILBRYSQ®.
- This includes the launch of UCB's core medicines (BIMZELX®, BRIVIACT®, EVENITY®, FINTEPLA®, RYSTIGGO® and ZILBRYSQ®) across all geographies by UCB and third-party distributors. If a medicine was launched in multiple indications, it is counted once only.

Key figures

Revenue

€ 7 741 M

(2024: € 6 152 M)

Adjusted EBITDA

€ 2 636 M

(2024: € 1 476 M)

Launches of UCB medicines across geographies²

56

(2024: 76)

Patients reached¹

>3.1 M

(2024: >3.1 M)

Molecules in clinical development

8

(2024: 9)

R&D/revenue ratio

24%


(2024: 29%)

* As of December 2025

UCB at a glance continued

Global footprint. Global impact.

Our culture of collaboration and curiosity is made up of a global team of people driven to push scientific boundaries and improve the health and wellbeing of the communities we are a part of. From our headquarters in Belgium and nearly 40 countries around the world, we work closely with a diverse network of patients, caregivers, healthcare professionals and other stakeholders.



- The number of employees is reported according to headcount at December 31, 2025. This is the number of active (including permanent and temporary) contract regular and expatriated UCB employees. It does not include the following employee groups: inactive employees, trainees, students and third-party apprentices.
- This includes the launch of UCB's core medicines (BIMZELX®, BRIVIACT®, EVENITY®, FINTEPLA®, RYSTIGGO® and ZILBRYSQ®) across all geographies by UCB and third-party distributors. If a medicine was launched in multiple indications, it is counted once only.
- 2025 total patient number is calculated using the Moving Annual Total (MAT) patients (Estimated Actual Treated) at the end of Q3 2025 as provided with input data from an external source. The total patient number gathers people who have accessed the following solutions: BIMZELX®, BRIVIACT®, CIMZIA®, EVENITY®, FINTEPLA®, KEPPRA®, NAYZILAM®, RYSTIGGO®, VIMPAT® and ZILBRYSQ®.

UCB at a glance continued





Unprecedented growth

UCB's growth is built on a proven history of ambition, innovation and execution. Today, our five core medicines – **BIMZELX®**, **RYSTIGGO®**, **ZILBRYSQ®**, **FINTEPLA®** and **EVENITY®** – are powering a decade of sustainable growth.

Through continued investment in global launches and a robust research and development (R&D) pipeline, we are also building the foundation of UCB's long-term future. This is supported by strategic resource allocation, disciplined cost management and the high energy and commitment shown by our employees.

Net sales by region


● Europe ● U.S. ● Rest of World



EVENITY®¹

€ 137 M
 Net sales

1.3 M
 patients reached



1. EVENITY® is being brought to people living with osteoporosis globally by Amgen, Astellas and UCB, with net sales outside Europe reported by the partners.

UCB at a glance continued

Innovating for the next generation

At UCB, innovation is never static. It’s a continuous cycle of learning, testing and refining aimed at addressing unmet needs and delivering differentiated solutions for people with severe diseases. Today, we are investing in the next wave of scientific breakthroughs, combining advances in combinatorial biology, digital antibody engineering and precision data science.

- Neurology
- Immunology



* In partnership with Biogen; 1st phase 3 study; 5-HT = 5-hydroxytryptamin or serotonin; CD40L = CD40 ligand; CDKL5 = cyclin-dependent kinase-like 5; H = half-year; IL = interleukin; FcRn = Neonatal Fragment Crystallizable Receptor; MOG = Myelin Oligodendrocyte Glycoprotein; PsA = Psoriatic Arthritis .